Exvastat receives prestigious Innovative Medicines Initiative grant to fund clinical study of imatinib in the treatment of COVID-19-associated ARDS.
Under the award, Exvastat will collaborate with Vrije Universitat, Amsterdam Medical Center, KABS (Canada) and Simbec-Orion to produce a reformulated version of the drug and test it in critically ill COVID-19 patients.
